Affymetrix appoints Frank Whitney president and CEO
This article was originally published in Scrip
Affymetrix has appointed Dr Frank Whitney president and chief executive officer, effective 1 July 2011. He will succeed Kevin King who has resigned as the company's president and CEO. Dr Whitney most recently served as president and CEO for Dionex Corporation, and has also held senior leadership positions at Panomics (which was acquired by Affymetrix) and Bio-Rad.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.